Tag: Arthritis: Misc.
October 2017 Briefing – Rheumatology
Here are what the editors at HealthDay consider to be the most important developments in Rheumatology for October 2017. This roundup includes the latest...
September 2017 Briefing – Rheumatology
Here are what the editors at HealthDay consider to be the most important developments in Rheumatology for September 2017. This roundup includes the latest...
Tofacitinib Superior to Placebo in Active Psoriatic Arthritis
Tofacitinib is superior for patients with inadequate response to TNF inhibitors or conventional DMARDs
September 2017 Briefing – Rheumatology
Here are what the editors at HealthDay consider to be the most important developments in Rheumatology for September 2017. This roundup includes the latest...
August 2017 Briefing – Rheumatology
Here are what the editors at HealthDay consider to be the most important developments in Rheumatology for August 2017. This roundup includes the latest...
July 2017 Briefing – Rheumatology
Here are what the editors at HealthDay consider to be the most important developments in Rheumatology for July 2017. This roundup includes the latest...
June 2017 Briefing – Rheumatology
Here are what the editors at HealthDay consider to be the most important developments in Rheumatology for June 2017. This roundup includes the latest...
May 2017 Briefing – Rheumatology
Here are what the editors at HealthDay consider to be the most important developments in Rheumatology for May 2017. This roundup includes the latest...
CDC: Prevalence of Arthritis 31.8% in Most Rural Areas of U.S.
About half of those with arthritis in rural and urban areas have arthritis-attributable activity limitation
Severe Cutaneous Adverse Effect From Tocilizumab Described
Diffuse, persistent, pruritic maculopapular rash developed 10 days after tocilizumab treatment
